Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 605-614 , July 2010

Synthesis, radiofluorination and first evaluation of [18F]fluorophenylsulfonyl- and [18F]fluorophenylsulfinyl-piperidines as serotonin 5-HT2A receptor antagonists for PET

Received 9 November 2009 ,Revised 4 February 2010 ,Accepted 8 March 2010.

References 

  1. Naughton M, Mulrooney JB, Leonard BE. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol. 2000;15:397–415
  2. Perry EK, Perry RH, Candy JM, Fairbairn AF, Blessed G, Dick DJ, et al. Cortical serotonin-S2 receptor-binding abnormalities in patients with Alzheimer-disease — comparisons with Parkinsons-disease. Neurosci Lett. 1984;51:353–357
  3. Dean B, Hayes W. Decreased frontal cortical serotonin(2A) receptors in schizophrenia. Schizophr Res. 1996;21:133–139
  4. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn C-G, Carr AA, et al. [11C]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci. 1996;58:187–192
  5. Johnson MP, Siegel BW, Carr AA. [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand. Naunyn-Schmiedeberg's Arch Pharmacol. 1996;354:205–209
  6. Leysen JE. In:  Boulton AA,  Baker GB,  Juorio AV editor. Drugs as Tools in Neurotransmitter Research. Neuromethods. Clifton, NJ: Humana Press; 1989;p. 299–350
  7. Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse. 2005;58:249–257
  8. Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, et al. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol. 1999;26:601–608
  9. Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G. Autoradiographic localization of 5-HT2A receptors in the human brain using [3H]M100907 and [11C]M100907. Synapse. 2000;38:421–431
  10. Price JC, Lopresti BJ, Mason NS, Holt DP, Huang Y, Mathis CA. Analyses of [18F]altanserin bolus injection PET data: I. Consideration of radiolabeled metabolites in baboons. Synapse. 2001;41:1–10
  11. Scott DO, Heath TG. Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat. J Pharm Biomed Anal. 1998;17:17–25
  12. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L. PET imaging of central 5-HT2A receptors with [11C]MDL 100,907. J Nucl Med. 1998;39:208–214
  13. Mathis CA, Mahmood K, Huang Y, Simpson NR, Gerdes JM, Price JC. Synthesis and preliminary in vivo evaluation of [11C]MDL 100907: a potent and selective radioligand for the 5-HT2A receptor system. Med Chem Res. 1996;6:1–10
  14. Herth MM, Debus F, Piel M, Palner M, Knudsen GM, Lüddens H, et al. Total synthesis and evaluation of [18F]MHMZ. Bioorg Med Chem Lett. 2008;18:1515–1519
  15. Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, et al. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab. 2000;20:899–909
  16. Mühlhausen U, Ermert J, Herth MM, Coenen HH. Synthesis, radiofluorination and first evaluation of (+/−)-[18F]MDL 100907 as serotonin 5-HT2A receptor antagonist for PET. J Label Compd Radiopharm. 2009;52:6–12
  17. Fletcher SR, Burkamp F, Blurton P, Cheng SKF, Clarkson R, O'Connor D, et al. 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT2A receptor antagonists. J Med Chem. 2002;45:492–503
  18. Blurton P, Burkamp F, Fletcher SR, MacLeod A. Phenyl-sulfonyl derivatives useful for treating e.g. schizophrenia and depression, being selective 5-HT2A receptor antagonists. PCT Int. Appl. 2000;WO 00/43362
  19. Hocke C. Untersuchungen zur n.c.a. 18F- und 123l-Markierung Subtypselektiver Derivate des 5-HT1A Rezeptorliganden WAY 100635. Ber Forsch Zent Jül. 2000;Jül-3895:1–133
  20. Tang S, Verdurand M, Joseph B, Lemoine L, Daoust A, Billard T, et al. Synthesis and biological evaluation in rat and cat of [18F]-12ST05 as a potential 5-HT6 PET radioligand. Nucl Med Biol. 2007;34:995–1002
  21. OECD Guideline for the Testing of Chemicals, 1989; available from: http://www.oecd.org/dataoecd/17/36/1948177.pdf.
  22. Laruelle M, Slifstein M, Huang A. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363–375
  23. Pazos A, Cortés R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: II. Serotonin-2 receptors. Brain Res. 1985;346:231–249
  24. Preece MA, Dalley JW, Theobald DE, Robbins TW, Reynolds GP. Region specific changes in forebrain 5-hydroxytryptamine1A and 5-hydroxytryptamine2A receptors in isolation-reared rats: an in vitro autoradiography study. Neuroscience. 2004;123:725–732
  25. Darchen F, Scherman D, Laduron PM, Henry JP. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol. 1988;33:672–677
  26. Qaim SM, Clark JC, Crouzel C, Guillaume M, Helmecke HJ, Nebeling B, et al. PET radionuclide production. In:  Stöcklin G,  Pike VW editor. Radiopharmaceuticals for PET. Dordrecht: Kluwer Academic Publishers; 1993;p. 15–26
  27. Coenen HH, Klatte B, Knöchel A, Schüller M, Stöcklin G. Preparation of n.c.a. [17-18F]-fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination. J Label Compd Radiopharm. 1986;23:455–466

PII: S0969-8051(10)00060-0

doi: 10.1016/j.nucmedbio.2010.03.003

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 605-614 , July 2010

Article Tools

* Image Usage & Resolution